The FDA’s Antimicrobial Drugs Advisory Committee voted in favor of pretomanid, as part of a combination regimen with bedaquiline and linezolid, for the treatment of pulmonary extensively drug resistant, treatment intolerant, or nonresponsive multidrug resistant tuberculosis.
The NDA for Talicia for the treatment of Helicobacter pylori (H. pylori) infection has been submitted to the FDA by RedHill Biopharma.
The FDA has approved Mavyret for the treatment of all 6 genotypes of hepatitis C virus in children 12 to 17 years old or weighing at least 45kg.
A recall of Ketorolac Tromethamine Injection has been issued following microbial growth contamination.
The Food and Drug Administration (FDA) has approved Dengvaxia (dengue tetravalent vaccine, live; Sanofi) for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4.
A new clinical guideline on the diagnosis and treatment of recurrent urinary tract infections in women was released by AUA.
The NDA for the long-acting injectable formulation of rilpivirine + cabotegravir (Janssen and ViiV Healthcare) for HIV has been submitted.
A recent report published in the American Journal of Case Reports describes a rare case of drug reaction with eosinophilia and systemic symptoms (DRESS)-induced agranulocytosis in a patient treated with the beta-lactam antibiotic oxacillin.
The FDA has expanded the approval of Avycaz to include pediatric patients aged ≥3 months for the treatment of complicated intra-abdominal infections.
A study shows Descovy for PrEP demonstrated that the treatment was non-inferior to Truvada for HIV prevention.
